283 related articles for article (PubMed ID: 30778794)
1. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Tanioka H; Honda M; Tanaka C; Morita Y; Ishibashi K; Kato T; Matsuda C; Kataoka M; Satake H; Munemoto Y; Kobayashi K; Takahashi M; Nakata K; Sakamoto J; Oba K; Mishima H
Int J Clin Oncol; 2019 Jul; 24(7):836-841. PubMed ID: 30778794
[TBL] [Abstract][Full Text] [Related]
2. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
3. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
4. Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Matsuda C; Honda M; Tanaka C; Fukunaga M; Ishibashi K; Munemoto Y; Hata T; Bando H; Oshiro M; Kobayashi M; Tokunaga Y; Fujii A; Nagata N; Oba K; Mishima H
Int J Clin Oncol; 2016 Jun; 21(3):566-72. PubMed ID: 26475356
[TBL] [Abstract][Full Text] [Related]
5. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Matsuda C; Honda M; Tanaka C; Kondo K; Takahashi T; Kosugi C; Tokunaga Y; Takemoto H; Kim HM; Sakamoto J; Oba K; Mishima H
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1035-1041. PubMed ID: 29644459
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
[TBL] [Abstract][Full Text] [Related]
9. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
[TBL] [Abstract][Full Text] [Related]
10. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Yamaguchi K; Taniguchi H; Komori A; Narita Y; Nitta S; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K; Mori K; Igarashi Y
BMC Cancer; 2015 Aug; 15():601. PubMed ID: 26311588
[TBL] [Abstract][Full Text] [Related]
11. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Jiang Z; Zhou A; Sun Y; Zhang W
BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
[TBL] [Abstract][Full Text] [Related]
12. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
Lee J; Shin SJ; Chung IJ; Kim TW; Chun HG; Shin DB; Kim YH; Song HS; Han SW; Kim JG; Kim SY; Choi YJ; Chung HC
Invest New Drugs; 2014 Jun; 32(3):561-8. PubMed ID: 24573743
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
Yoshida M; Takagane A; Miyake Y; Shimada K; Nagata N; Sato A; Ogata Y; Fukunaga M; Otsuka K; Takahashi T; Matsumoto H; Kagimura T; Tsuji A
Oncology; 2016; 91(1):24-30. PubMed ID: 27229742
[TBL] [Abstract][Full Text] [Related]
14. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Nakamoto Y; Noda M; Mikami R; Tokunaga Y; Okumoto T; Kawamura T; Fujiwara H; Doi S; Tomita N
Int J Clin Oncol; 2020 Jul; 25(7):1285-1290. PubMed ID: 32200481
[TBL] [Abstract][Full Text] [Related]
16. Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Sadahiro S; Suzuki T; Okada K; Saito G; Miyakita H; Ogimi T; Chan LF; Kamei Y
Oncology; 2020; 98(9):637-642. PubMed ID: 32474564
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
18. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C
Ann Oncol; 2018 Mar; 29(3):624-631. PubMed ID: 29293874
[TBL] [Abstract][Full Text] [Related]
19. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Winther SB; Zubcevic K; Qvortrup C; Vestermark LW; Jensen HA; Krogh M; Sorbye H; Pfeiffer P;
Acta Oncol; 2016 Jul; 55(7):881-5. PubMed ID: 27181284
[TBL] [Abstract][Full Text] [Related]
20. [Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
Maruo H; Suzuki K; Ishikawa S; Murakami T; Higashi Y; Shoji T; Yamazaki M; Taniguchi M; Nishiyama R
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2583-6. PubMed ID: 25596052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
